Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
You may also be interested in...
Spain's drug industry appeals against a court ruling allowing local drug funding decisions.
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.